Skip to main content
OpenTrials
Completed

NCT Number: NCT02158585

Study of Lamotrigine to Treat Ménière's Disease

This double-blinded study evaluates the frequency of vertigo attacks and the quality of life of patients diagnosed with Ménière's disease after being randomly assigned to take a placebo or lamotrigine.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male and female participants aged 18 years or older
  • Diagnosed with unilateral definite Ménière's disease according to the AAO-HNS 1995 criteria, confirmed by an ENT
  • Active vertigo: at least two Ménière's vertigo attacks (defined as lasting 20 minutes or longer and associated with tinnitus, ear fullness, or low frequency hearing loss and nausea/vomiting) every four weeks during the eight-week qualification period and at least two more Ménière's vertigo attacks during the lead-in phase prior to randomization
  • Documented unilateral lower frequency hearing loss defined as the four-tone average (arithmetic mean rounded to the nearest whole number) of the pure-tone thresholds at 0.25, 0.5, 1 and 2 kilohertz (kHz) more than or equal to 25 decibels (dB) of the worse audiogram during the six months before screening
  • Have tried diuretics for at least one month and discontinued treatment due to continued vertigo attacks
  • All other co-existing medical or psychiatric conditions are stable, and no greater than moderate severity
  • Willing to avoid pregnancy during the entirety of the study (abstinence or two forms of acceptable birth control, such as condoms and oral contraceptives)

Exclusion criteria

  • Bilateral Ménière's disease
  • Current or past history of migraine
  • Any other neuro-otologic disease or major vestibular abnormality found during screening that could confound the evaluation of Ménière's symptoms
  • Previous intolerance or sensitivity to lamotrigine
  • On any prohibited medication within four weeks prior to the study
  • History of tympanostomy tubes with evidence of perforation or lack of closure
  • IT gentamicin injections or endolymphatic sac surgery within the last year
  • History of or current immunodeficiency disease, nephrolithiasis, hypertension, cardiac disease, arrhythmia, hypercholesterolemia, hemiplegic/basilar migraine, stroke, diabetes, vascular disease or kidney disease
  • Family history of unexplained deafness
  • Pregnant or breastfeeding
  • Current diseases or conditions that may be associated with an altered perception of processing stimuli
  • Current severe medical condition(s) that in the view of the investigator prohibits participation
  • Previously used the investigational drug
  • Current non-vertiginous dizziness (orthostatic or panic disorder) unless it could be clearly differentiated from Ménière's attacks by the participant

Treatment and study plan

Lamotrigine

Drug

Lamotrigine will be taken orally on a daily basis for the duration of 20 weeks, consisting of a six-week titration, 12-week study period, and two-week taper. Possible doses for patients are 25mg twice a day, 50mg twice a day, and 100 mg twice a day during titration; 150mg twice a day for the 12-week study period; 150mg once a day for Week 1 of the taper; and 75mg once a day for Week 2 of the taper. Each increase in dose will be maintained for two weeks before deciding to further increase or decrease based on tolerability. Patients who discontinue at any point of the study will have a two-week taper consisting of the current dose once a day for one week followed by half the dose once a day for another week.

Other names: Lamictal, 3,5-diamino-6-(2,3-dichlorophenyl)-as-triazine, U3H27498KS

Placebo

Drug

The placebo will match the lamotrigine dosage, frequency and duration.

Other names: microcrystalline cellulose

Primary outcomes

  1. Change in Ménière's Vertigo Attack Frequency Between Lamotrigine and Placebo Group

    Time frame: Duration of 12-week pre-treatment and 12-week study period (treatment)

    Measured with a daily questionnaire

  2. Change in Ménière's Vertigo Attack Frequency Within Lamotrigine Group

    Time frame: Duration of 12-week pre-treatment and 12-week study period (treatment)

    Measured with daily questionnaire

Secondary outcomes

  1. Difference in Ménière's Vertigo Attacks in Three-Week Intervals Between Lamotrigine and Placebo Groups

    Time frame: Duration of Week 16 to 18

    Measured with a daily questionnaire.

  2. Improvement in Pure Tone Average in the Affected Ear

    Time frame: Prior to randomization and at completion of 12-week study period

    Measured using the average of 500, 1000, 2000, and 3000 Hz presentation level (dB)

  3. Improvement in Symptoms Severity

    Time frame: 12-week pre-treatment period; 6 week titration; 12-week study period (treatment)

    Based of rating on Clinical Global Impression of Change (CGI) score of blinded physician

  4. DHI Scores

    Time frame: Baseline (Week 1) and end of study (Week 18)

    Dizziness Handicap Inventory (DHI). Minimum score=0. Maximum score=100. Higher scores mean a worse outcome.

Sponsors and collaborators

Lead sponsor

Dent Neuroscience Research Center

Other

Collaborators

  • University at Buffalo

Registry information

Official study title

Lamotrigine for Ménière's Disease: a Double-blind, Placebo-controlled Pilot Study

Important dates

Study start
2014
Primary completion
2017
Study completion
2017
First posted
Jun 9, 2014
Registry last updated
Jun 22, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.